Revisiting the commercial-academic interface in medical journals

BMJ (Online)

Volumn 350, Issue , 2015, Pages

  Loder, Elizabeth ^a   Brizzell, Catherine ^a   Godlee, Fiona ^a  

^a London   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL PRACTICE; COMMERCIAL PHENOMENA; EDITORIAL; HUMAN; MEDICAL LITERATURE; PATIENT SAFETY; PRIORITY JOURNAL; PROFESSIONAL KNOWLEDGE; PUBLIC-PRIVATE PARTNERSHIP; PUBLICATION; PUBLISHING; SCIENTIFIC LITERATURE; CONFLICT OF INTEREST; DRUG INDUSTRY; ETHICS; INTERPERSONAL COMMUNICATION; PUBLIC RELATIONS; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; CONFLICT OF INTEREST; DISCLOSURE; DRUG INDUSTRY; EDITORIAL POLICIES; INTERPROFESSIONAL RELATIONS;

EID: 84936984887     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.h2957     Document Type: Editorial

References (17)

1. Ipsos Mori. Reputation snapshot for the pharmaceutical sector. 2012. www.ipsos.com/public-affairs/sites/www.ipsos.com.public-affairs/files/Pharma%20Reputation%20Snapshot%20-%20INTL.pdf.
2. Kesselheim AS, Robertson CT, Myers JA, et al. A randomized study of how physicians interpret research funding disclosures. N Engl J Med 2012;367:12.
3. Schroter S, Morris J, Chaudhry S, Smith, R, Barratt H. Does the type of competing interest affect readers' perceptions of the credibility of research? Randomised trial. BMJ 2004;328:742.
4. Novella S. Demonizing big pharma. 22 Apr 2010. www.sciencebasedmedicine.org/demonizing-big-pharma/
5. Drazen JM. Revisiting the commercial-academic interface. N Engl J Med 2014;372;19:1853-4.
6. Rosenbaum L. Reconnecting the dots-reinterpreting industry-physician relations. N Engl J Med 2015;372:1860-4.
7. Rosenbaum L. Understanding bias-the case for careful study. N Engl J Med 2015;372:1959-63.
8. Rosenbaum L. Beyond moral outrage-weighing the trade-offs of COI regulation. N Engl J Med 2015;372:2064-8.
9. Chew M, Brizzell C, Abbasi K, Godlee F. Medical journals and industry ties. BMJ 2014;349:g7197.
10. Jain A, Nundy S, Abbasi K. Corruption: medicine's dirty open secret. BMJ 2014;348:g4184.
11. Jourdan A, Ruwitch J. RTP-Big Pharma Beware: GSK China case may be just the beginning. Reuters 2014 May 18. www.reuters.com/article/2014/05/18/gsk-china-corruption-idUSL3N0O40AG20140518.
12. Cain DM, Loewsenstein G, Moore DA. The dirt on coming clean: perverse effects of disclosing conflicts of interest. www.researchgate.net/profile/Don-Moore2/publication/24101611-The-Dirt-on-Coming-Clean-Perverse-Effects-of-Disclosing-Conflicts-of-Interest/links/00463526906bc03255000000.pdf.
13. Humphries C. Deeply conflicted. Boston Globe 2011 May 15. www.boston.com/bostonglobe/ideas/articles/2011/05/15/deeply-conflicted/?page=3.
14. Anderson ML, Chiswell K, Peterson ED, Tasneem A, Topping J, Califf RM. Compliance with results reporting at ClinicalTrials.gov. N Engl J Med 2015;372:1031-9.
15. MRCT Center at Harvard. Committed leaders gather to drive clinical trial data transparency solutions. 30 Apr 2015. http://mrct.globalhealth.harvard.edu/news/committed-leaders-gather-drive-clinical-trial-data-transparency-solutions.
16. Light DW, Lexchin J, Darrow JJ. Institutional corruption of pharmaceuticals and the myth of safe and effective drugs. J Law Med Ethics 2013;14:590-610.
17. Steinbrook R, Kassirer JP, Angell M. Justifying conflicts of interest in medical journals: a very bad idea. BMJ 2015;350:h2942.